Neuberger Berman Group LLC Fate Therapeutics Inc Transaction History

Neuberger Berman Group LLC

$123 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Nov 14, 2024	BUY	$1.65 - $3.94 $17,551 - $41,909	10,637 New	10,637 $39,000
Q4 2023 Feb 09, 2024	BUY	$1.65 - $3.94 $17,551 - $41,909	10,637 New	10,637 $39,000
Q3 2022 Nov 15, 2022	SELL	$21.04 - $36.06 $5,596 - $9,591	-266 Reduced 0.07%	376,683 $8.44 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $333,499 - $795,109	18,757 Added 5.24%	376,949 $9.34 Million
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $173,747 - $352,999	5,856 Added 1.66%	358,192 $13.9 Million
Q4 2021 Feb 11, 2022	SELL	$47.84 - $64.34 $1.57 Million - $2.11 Million	-32,851 Reduced 8.53%	352,336 $20.6 Million
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $7.4 Million - $12 Million	124,894 Added 47.98%	385,187 $22.7 Million
Q2 2021 Aug 13, 2021	BUY	$67.25 - $92.52 $13.7 Million - $18.8 Million	203,610 Added 359.21%	260,293 $22.6 Million
Q1 2021 May 13, 2021	SELL	$72.16 - $117.4 $311,514 - $506,815	-4,317 Reduced 7.08%	56,683 $4.64 Million
Q3 2020 Nov 12, 2020	BUY	$30.41 - $40.5 $729,840 - $972,000	24,000 Added 64.86%	61,000 $2.44 Million
Q1 2020 May 14, 2020	SELL	$17.28 - $31.88 $915,840 - $1.69 Million	-53,000 Reduced 58.89%	37,000 $821,000
Q4 2019 Feb 12, 2020	SELL	$13.39 - $20.73 $232,986 - $360,702	-17,400 Reduced 16.2%	90,000 $1.76 Million
Q3 2019 Nov 13, 2019	BUY	$15.47 - $22.5 $176,358 - $256,500	11,400 Added 11.88%	107,400 $1.67 Million
Q2 2019 Aug 13, 2019	BUY	$15.61 - $20.44 $561,960 - $735,840	36,000 Added 60.0%	96,000 $1.95 Million
Q4 2018 Feb 12, 2019	SELL	$11.48 - $16.98 $688,800 - $1.02 Million	-60,000 Reduced 50.0%	60,000 $770,000
Q3 2018 Nov 13, 2018	BUY	$8.75 - $16.29 $918,750 - $1.71 Million	105,000 Added 700.0%	120,000 $1.96 Million
Q2 2018 Aug 13, 2018	SELL	$9.16 - $13.48 $1.27 Million - $1.86 Million	-138,250 Reduced 90.21%	15,000 $170,000
Q1 2018 May 08, 2018	SELL	$6.3 - $13.77 $126,000 - $275,400	-20,000 Reduced 11.54%	153,250 $1.5 Million
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $158,585 - $267,260	40,250 Added 30.26%	173,250 $1.06 Million
Q3 2017 Nov 15, 2017	BUY	$2.6 - $4.31 $345,800 - $573,230	133,000	133,000 $527,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.

Account